InterpaceBiosciences_New Logo.png
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
05 juin 2023 16h05 HE | Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS)...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
11 mai 2021 16h47 HE | Interpace Biosciences, Inc.
 ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business  ● Q2 Revenue Expected to Exceed $11 million  ● On Track to Exceed Full Year 2021...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
03 mai 2021 08h00 HE | Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
LOGO.jpg
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
05 avr. 2021 16h05 HE | Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...
LOGO.jpg
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
26 oct. 2020 06h30 HE | Interpace Biosciences, Inc.
 Study Demonstrates Superior Performance of ThyGeNEXT® and ThyraMIR® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
LOGO.jpg
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
10 mars 2020 06h55 HE | Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced...
LOGO.jpg
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
02 mars 2020 06h55 HE | Interpace Biosciences, Inc.
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s...
LOGO.jpg
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
13 janv. 2020 06h55 HE | Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...
LOGO.jpg
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
06 janv. 2020 06h55 HE | Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
LOGO.jpg
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
17 déc. 2019 06h55 HE | Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...